Harvey-Bradshaw Index Calculator
Crohn’s Disease Activity Assessment Tool
What is the Harvey-Bradshaw Index?
The Harvey-Bradshaw Index (HBI) is a simplified clinical tool used to assess disease activity in patients with Crohn’s disease. Developed in 1980 as a simpler alternative to the Crohn’s Disease Activity Index (CDAI), it provides a quick and practical method for evaluating symptoms and monitoring treatment response.
The HBI is widely used in clinical practice and research to quantify Crohn’s disease activity, track disease progression, and evaluate treatment effectiveness without requiring laboratory tests or complex calculations.
Clinical Significance
Crohn’s disease is characterized by periods of remission and flare-ups with varying severity. The HBI helps clinicians objectively measure disease activity, make treatment decisions, and monitor patient progress over time. It’s particularly valuable for its simplicity and ability to be completed quickly during clinic visits.
Assessment Parameters
The HBI evaluates five key clinical parameters:
| Parameter | Description | Scoring |
|---|---|---|
| General Well-being | Patient’s overall feeling of health | 0 (Very well) to 4 (Terrible) |
| Abdominal Pain | Severity of abdominal discomfort | 0 (None) to 3 (Severe) |
| Number of Liquid Stools | Daily frequency of loose stools | Actual count per day |
| Abdominal Mass | Palpable mass in abdomen | 0 (None) to 3 (Definite and tender) |
| Complications | Presence of specific complications | 1 point each (Arthritis, Uveitis, Erythema Nodosum, etc.) |
Harvey-Bradshaw Index Formula
Advantages Over CDAI
The HBI was developed as a simplified version of the more complex Crohn’s Disease Activity Index (CDAI). Key advantages include:
- No laboratory tests required
- Faster to complete (typically 1-2 minutes)
- Easier for patients to self-assess between visits
- Good correlation with CDAI for clinical decision-making
HBI Calculator
Complete the following assessment to calculate the Harvey-Bradshaw Index for Crohn’s disease activity.
Score Interpretation
HBI scores are categorized into disease activity levels with associated clinical implications:
Treatment Implications
Clinical Remission (HBI ≤ 4): Continue current maintenance therapy with regular monitoring.
Mild Disease (HBI 5-7): Consider optimizing current medications, adding symptomatic treatments, or mild anti-inflammatory agents.
Moderate Disease (HBI 8-16): Often requires treatment escalation, addition of corticosteroids, or adjustment of immunomodulators/biologics.
Severe Disease (HBI > 16): Typically requires aggressive treatment with corticosteroids, biologics, or hospitalization for severe cases.
Limitations and Considerations
While the HBI is a valuable clinical tool, it should be used in conjunction with:
- Objective laboratory markers (CRP, ESR, fecal calprotectin)
- Endoscopic evaluation when indicated
- Imaging studies for complications or disease extent
- Nutritional assessment
- Quality of life measures
Comparison with Other Indices
The HBI is one of several tools used to assess Crohn’s disease activity:
- Crohn’s Disease Activity Index (CDAI): More comprehensive but complex; requires 7-day diary
- Simple Crohn’s Disease Activity Index (sCDAI): Simplified version of CDAI
- Patient Harvey-Bradshaw Index (pHBI): Patient-reported version of HBI
Note: This calculator provides an estimate based on the standard HBI calculation. Treatment decisions should always be made in consultation with a gastroenterologist considering the complete clinical picture, including laboratory results and endoscopic findings.
The Harvey-Bradshaw Index (HBI) is a simplified clinical tool used to quantify the disease activity of Crohn’s Disease. Devised in 1980 by Richard Harvey and Stephen Bradshaw, it was designed as a more practical alternative to the cumbersome Crohn’s Disease Activity Index (CDAI) (Harvey & Bradshaw, 1980).
While the CDAI requires patients to keep a detailed seven-day diary of symptoms, the HBI can be completed during a single clinical encounter, making it the "gold standard" for rapid bedside assessment and long-term outpatient monitoring.
The Five Components of the HBI
The index consists of five clinical parameters based on the patient's status from the previous day. Unlike other gastrointestinal scores, it does not require laboratory data or endoscopic findings for the basic calculation.
1. General Well-being (0–4)
The patient rates how they felt yesterday:
- 0: Very well
- 1: Slightly below par
- 2: Poor
- 3: Very poor
- 4: Terrible
2. Abdominal Pain (0–3)
- 0: None
- 1: Mild
- 2: Moderate
- 3: Severe
3. Number of Liquid Stools (Point per bowel movement)
The patient records the number of liquid or very soft stools passed in the previous 24 hours. (e.g., 5 stools = 5 points).
4. Abdominal Mass (0–3)
This is the only component requiring a physical examination by a clinician:
- 0: None
- 1: Dubious
- 2: Definite
- 3: Definite and tender
5. Complications (1 point per complication)
The clinician checks for the presence of "extra-intestinal manifestations" or specific local complications:
- Arthralgia (joint pain)
- Uveitis (eye inflammation)
- Erythema nodosum or Pyoderma gangrenosum (skin lesions)
- Aphthous ulcers (mouth sores)
- Anal fissures, fistulae, or abscesses
Clinical Interpretation and Scoring
The total score provides a snapshot of whether the disease is controlled or flaring.
| HBI Score | Disease Activity | Clinical Status |
| < 5 | Remission | Disease is well-controlled. |
| 5 – 7 | Mild | Early signs of a flare; may require medication adjustment. |
| 8 – 16 | Moderate | Significant impact on daily life; active inflammation likely. |
| > 16 | Severe | High risk of hospitalization or surgical intervention. |
HBI vs. CDAI: Which is better?
The primary advantage of the HBI is feasibility. Correlation studies have shown a very high degree of agreement ($r = 0.93$) between the HBI and the more complex CDAI (Best, 2006).
However, because the HBI relies heavily on the "number of liquid stools," it can sometimes be misleading in patients who have had significant bowel resections or those with co-existing Irritable Bowel Syndrome (IBS), where high stool frequency may not always indicate active Crohn's inflammation. In these cases, clinicians often supplement the HBI with objective markers like Fecal Calprotectin or C-Reactive Protein (CRP).
References
- Harvey, R. F., & Bradshaw, J. M. (1980). A simple index of Crohn's-disease activity. The Lancet, 315(8167), 514-515. https://doi.org/10.1016/S0140-6736(80)91049-3
- Best, W. R. (2006). Predicting the Crohn's disease activity index from the Harvey-Bradshaw index. Clinical Gastroenterology and Hepatology, 4(3), 356-359.
- Vermeire, S., et al. (2002). The use of C-reactive protein as a predictor of drug response with infliximab in Crohn's disease. Alimentary Pharmacology & Therapeutics.
- Satsangi, J., et al. (2006). The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut, 55(6), 749-753.
